Fresenius Kabi introduces the posaconazole injection, a generic substitute for Noxafil, for use in treating or preventing serious fungal infections in adults and children who have an increased chance of getting these infections due to a weakened immune system. Made in the US, the injection is the newest addition to Fresenius Kabi’s portfolio of more than 30 anti-infective molecules. The injection is available in a 300 mg per 16.7 mL vial. Posaconazole injection is used to treat invasive aspergillosis in adults and teenagers 13 years of age and older. It is also used to prevent invasive aspergillus and candida infections in patients who are severely immunocompromised, including adults and pediatric patients age 2 or older.